MX2018004406A - Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae. - Google Patents
Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.Info
- Publication number
- MX2018004406A MX2018004406A MX2018004406A MX2018004406A MX2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A
- Authority
- MX
- Mexico
- Prior art keywords
- klebsiella pneumoniae
- monoclonal antibody
- antibody targeting
- bactericidal
- bactericidal monoclonal
- Prior art date
Links
- 241000588747 Klebsiella pneumoniae Species 0.000 title abstract 2
- 230000000844 anti-bacterial effect Effects 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- G01N2333/26—Klebsiella (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
Abstract
Un anticuerpo IgG monoclonal bactericida humano o humanizado que reconoce específicamente el antígeno D-galactán-II de la Klebsiella pneumoniae O1 el cual se caracteriza por una actividad de CDC bactericida, su método de producción, uso médico y diagnóstico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15190136 | 2015-10-16 | ||
| PCT/EP2016/074728 WO2017064258A1 (en) | 2015-10-16 | 2016-10-14 | Bactericidal monoclonal antibody targeting klebsiella pneumoniae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018004406A true MX2018004406A (es) | 2019-07-01 |
Family
ID=54359802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004406A MX2018004406A (es) | 2015-10-16 | 2016-10-14 | Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180298084A1 (es) |
| EP (1) | EP3362474A1 (es) |
| JP (1) | JP2018533938A (es) |
| KR (1) | KR20180084793A (es) |
| CN (1) | CN108602880A (es) |
| AU (1) | AU2016336901A1 (es) |
| BR (1) | BR112018007483A2 (es) |
| CA (1) | CA3000901A1 (es) |
| IL (1) | IL258475A (es) |
| MX (1) | MX2018004406A (es) |
| RU (1) | RU2018117651A (es) |
| WO (1) | WO2017064258A1 (es) |
| ZA (1) | ZA201802136B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11447542B2 (en) | 2016-08-05 | 2022-09-20 | Medimmune, Llc | Anti-O2 antibodies and uses thereof |
| KR20190064636A (ko) | 2016-10-19 | 2019-06-10 | 메디뮨 엘엘씨 | 항-o1 항체 및 이의 용도 |
| KR102581500B1 (ko) * | 2021-01-20 | 2023-09-20 | 서울대학교산학협력단 | 폐렴간균 독소-항독소 시스템을 표적으로 하는 항균 펩타이드 및 화합물, 및 이들의 용도 |
| KR102657660B1 (ko) * | 2021-06-15 | 2024-04-15 | 경상국립대학교산학협력단 | 폐렴간균 검출용 신규한 펩타이드 |
| WO2023025173A1 (zh) * | 2021-08-25 | 2023-03-02 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别肺炎克雷伯菌o1抗原的抗体及其应用 |
| IT202300000924U1 (it) * | 2023-01-23 | 2024-12-22 | Philomena Dove | Cucitura all-up leggins seamless |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| CA2625183C (en) * | 2005-10-04 | 2019-09-03 | Inimex Pharmaceuticals Inc. | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
| CA3187687A1 (en) | 2007-09-14 | 2009-03-19 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP3336225B1 (en) | 2010-07-16 | 2020-02-19 | Adimab, LLC | Antibody libraries |
| WO2012146630A1 (en) * | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
| US20150197558A1 (en) * | 2013-09-26 | 2015-07-16 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
-
2016
- 2016-10-14 JP JP2018519692A patent/JP2018533938A/ja active Pending
- 2016-10-14 US US15/768,274 patent/US20180298084A1/en not_active Abandoned
- 2016-10-14 WO PCT/EP2016/074728 patent/WO2017064258A1/en not_active Ceased
- 2016-10-14 BR BR112018007483A patent/BR112018007483A2/pt not_active Application Discontinuation
- 2016-10-14 RU RU2018117651A patent/RU2018117651A/ru not_active Application Discontinuation
- 2016-10-14 CN CN201680070824.3A patent/CN108602880A/zh active Pending
- 2016-10-14 CA CA3000901A patent/CA3000901A1/en not_active Abandoned
- 2016-10-14 MX MX2018004406A patent/MX2018004406A/es unknown
- 2016-10-14 AU AU2016336901A patent/AU2016336901A1/en not_active Abandoned
- 2016-10-14 KR KR1020187013940A patent/KR20180084793A/ko not_active Withdrawn
- 2016-10-14 EP EP16782053.9A patent/EP3362474A1/en not_active Withdrawn
-
2018
- 2018-04-01 IL IL258475A patent/IL258475A/en unknown
- 2018-04-03 ZA ZA2018/02136A patent/ZA201802136B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018117651A (ru) | 2019-11-20 |
| CN108602880A (zh) | 2018-09-28 |
| EP3362474A1 (en) | 2018-08-22 |
| ZA201802136B (en) | 2019-09-25 |
| IL258475A (en) | 2018-05-31 |
| CA3000901A1 (en) | 2017-04-20 |
| KR20180084793A (ko) | 2018-07-25 |
| BR112018007483A2 (pt) | 2018-10-23 |
| AU2016336901A1 (en) | 2018-05-10 |
| US20180298084A1 (en) | 2018-10-18 |
| WO2017064258A1 (en) | 2017-04-20 |
| JP2018533938A (ja) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004406A (es) | Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae. | |
| MY184154A (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| EP3689909A4 (en) | Tigit antibody, antigen-binding fragment thereof, and medical use thereof | |
| PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
| MX2021005396A (es) | Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo. | |
| PH12017500819A1 (en) | Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production | |
| TN2016000559A1 (en) | Monoclonal antibodies against her2 epitope and methods of use thereof | |
| IL281272A (en) | Humanized antibodies against C5 and their uses | |
| JOP20170004B1 (ar) | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته | |
| MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
| MX2018011633A (es) | Diagnostico no invasivo de esteatohepatitis no alcoholica. | |
| EP4249515A3 (en) | Humanized or chimeric cd3 antibodies | |
| MX2017005987A (es) | Anticuerpos anti-interleucina(il)-1beta y metodos de uso. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| MA39821A (fr) | Molécules de liaison spécifiques de l'il-21 et leurs utilisations | |
| EP3778636A4 (en) | ANTI-CD27 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND ASSOCIATED MEDICAL USE | |
| IL274951A (en) | Human antibodies directed against human tissue factor | |
| MX2014010987A (es) | Tratamiento de esclerosis multiple con anticuerpo anti-cd19. | |
| MX2019015914A (es) | Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide. | |
| EA201892313A1 (ru) | Гуманизированные антитела против clever-1 и их применение | |
| PH12019500434A1 (en) | Anti-gm-csf antibodies and uses thereof | |
| MX2018012061A (es) | Inhibidor monovalente de la interaccion hutnfr1. | |
| EP3524624A4 (en) | ANTI-CD27 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF, AND ITS MEDICAL USE | |
| IL269655B1 (en) | An erbb-2-targeted agent and a bispecific antibody with antigen-binding sites that bind epitopes on the extracellular part of erbb-2 and erbb-3, for the treatment of individuals with erbb-2, erbb-2/erbb-3 positive cancer tumors | |
| PH12021550991A1 (en) | Monoclonal antibody that specifically binds to cd20 |